On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...